Published in Immunology on December 01, 2002
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev (2009) 3.23
Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov (2012) 2.29
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res (2009) 2.01
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood (2010) 2.01
A guide to immunometabolism for immunologists. Nat Rev Immunol (2016) 1.41
Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J (2010) 1.36
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol (2007) 1.23
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy (2009) 1.10
Gene expression patterns in experimental colitis in IL-10-deficient mice. Inflamm Bowel Dis (2009) 1.08
Inflammation and repeated infections in CGD: two sides of a coin. Cell Mol Life Sci (2011) 1.03
The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects. J Cell Mol Med (2009) 1.01
Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2008) 0.97
Emerging roles of pericytes in the regulation of the neurovascular unit in health and disease. J Neuroimmune Pharmacol (2014) 0.97
An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. PLoS One (2011) 0.97
Regulatory T cell induction, migration, and function in transplantation. J Immunol (2012) 0.96
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology (2013) 0.94
Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways Ex vivo. Retrovirology (2014) 0.93
Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease. PLoS One (2015) 0.90
Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. J Gen Virol (2013) 0.87
IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease. Int J Tryptophan Res (2010) 0.86
Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol (2011) 0.86
Gatekeepers of intestinal inflammation. Inflamm Res (2010) 0.85
Verification of association of elevated serum IDO enzyme activity with acute rejection and low CD4-ATP levels with infection. Transplantation (2013) 0.85
Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int J Tryptophan Res (2010) 0.85
Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration. Semin Immunopathol (2015) 0.84
Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing-Remitting Multiple Sclerosis. PLoS One (2015) 0.83
Immune biomarker panel monitoring utilizing IDO enzyme activity and CD4 ATP levels: prediction of acute rejection vs. viral replication events. Pediatr Transplant (2011) 0.82
T cell tolerance induced by therapeutic antibodies. Philos Trans R Soc Lond B Biol Sci (2005) 0.81
Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation. Blood (2005) 0.81
Understanding the role of the kynurenine pathway in human breast cancer immunobiology. Oncotarget (2016) 0.80
Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways. Immunology (2005) 0.80
Blockade of indoleamine 2,3-dioxygenase reduces mortality from peritonitis and sepsis in mice by regulating functions of CD11b+ peritoneal cells. Infect Immun (2014) 0.79
Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model. Arthritis Res Ther (2015) 0.79
Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett (2015) 0.78
Reduced Dendritic Cells Expressing CD200R1 in Children with Inflammatory Bowel Disease: Correlation with Th17 and Regulatory T Cells. Int J Mol Sci (2015) 0.78
Metabolic Instruction of Immunity. Cell (2017) 0.76
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. J Neural Transm (Vienna) (2012) 0.76
Amelioration of 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice by immunoregulatory dendritic cells. J Gastroenterol (2011) 0.76
Opposing Roles of Interferon-Gamma on Cells of the Central Nervous System in Autoimmune Neuroinflammation. Front Immunol (2015) 0.76
Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Curr Opin Immunol (2017) 0.76
Indoleamine-2,3-dioxygenase enzyme expression and activity in polarized dendritic cells. Cytotherapy (2009) 0.75
Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth. Oncotarget (2016) 0.75
Induction of indoleamine 2,3-dioxygenase by Borrelia burgdorferi in human immune cells correlates with pathogenic potential. J Leukoc Biol (2014) 0.75
Crosstalk between Tryptophan Metabolism and Cardiovascular Disease, Mechanisms, and Therapeutic Implications. Oxid Med Cell Longev (2017) 0.75
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. BMC Infect Dis (2014) 0.75
The Importance of Dendritic Cells in Maintaining Immune Tolerance. J Immunol (2017) 0.75
Immuno-regulatory function of indoleamine 2,3 dioxygenase through modulation of innate immune responses. PLoS One (2013) 0.75
Indoleamine 2,3-dioxygenase in human hematopoietic stem cell transplantation. Int J Tryptophan Res (2010) 0.75
c-kit plays a critical role in induction of intravenous tolerance in experimental autoimmune encephalomyelitis. Immunol Res (2015) 0.75
Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase. PLoS One (2014) 0.75
Kynurenine Pathway in Skin Cells: Implications for UV-Induced Skin Damage. Int J Tryptophan Res (2012) 0.75
Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol (2017) 0.75
Human renal tubular epithelial cells suppress alloreactive T cell proliferation. Clin Exp Immunol (2015) 0.75
Immunohistochemical studies of the kynurenine pathway in morphea. Int J Tryptophan Res (2013) 0.75
Placental expression of indoleamine 2,3-dioxygenase. Wien Med Wochenschr (2012) 0.75
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. Cell Metab (2017) 0.75
Aspects of Tryptophan and Nicotinamide Adenine Dinucleotide in Immunity: A New Twist in an Old Tale. Int J Tryptophan Res (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 9.80
Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 7.28
Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J (1991) 5.30
Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 5.26
The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med (1992) 4.58
Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today (1999) 3.74
A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med (1996) 3.66
Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol (2000) 3.46
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med (1997) 2.73
Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J Exp Med (2000) 2.29
Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol (2001) 2.23
Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002) 2.14
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol (2002) 1.69
T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv Immunol (1999) 1.64
IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity (1998) 1.64
Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony-stimulating factor and interferon gamma. J Exp Med (1995) 1.42
Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol (1998) 1.26
CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol (2001) 1.25
Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes (2002) 1.23
Dichotomy between naïve and memory CD4(+) T cell responses to Fas engagement. Proc Natl Acad Sci U S A (1999) 1.06
Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells. Proc Natl Acad Sci U S A (1996) 1.02
Induction of tolerance to self MHC class I molecules expressed under the control of milk protein or beta-globin gene promoters. Int Immunol (1994) 1.02
Effects of different antigenic microenvironments on the course of CD8+ T cell responses in vivo. Int Immunol (1996) 1.00
Inhibition of collagenase and stromelysin gene expression by interferon-gamma in human dermal fibroblasts is mediated in part via induction of tryptophan degradation. J Clin Invest (1995) 1.00
The role of T cell apoptosis in transplantation tolerance. Curr Opin Immunol (2000) 0.91
Dendritic cells and prospects for transplantation tolerance. Curr Opin Immunol (2000) 0.89
Self major histocompatibility complex class I antigens expressed solely in lymphoid cells do not induce tolerance in the CD4+ T cell compartment. J Exp Med (1996) 0.84
Functional characterization of Jurkat T cells rescued from CD95/Fas-induced apoptosis through the inhibition of caspases. Biochem Biophys Res Commun (2000) 0.84
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 4.53
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol (2009) 2.83
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol (2004) 2.77
Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 2.59
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol (2008) 2.55
Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol (2003) 2.54
Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol (2005) 2.51
Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol (2006) 2.40
Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2012) 2.37
Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol (2004) 2.30
Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 2.22
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol (2005) 2.18
Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002) 2.14
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol (2004) 2.13
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med (2010) 2.12
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood (2007) 2.12
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer (2002) 2.10
IDO and tolerance to tumors. Trends Mol Med (2004) 2.03
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol (2007) 1.89
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics (2012) 1.80
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol (2002) 1.69
The tumor-draining lymph node as an immune-privileged site. Immunol Rev (2006) 1.57
T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med (2014) 1.56
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood (2005) 1.54
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44
Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis (2005) 1.41
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest (2014) 1.38
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.37
Tryptophan catabolism and regulation of adaptive immunity. J Immunol (2003) 1.36
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood (2009) 1.35
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood (2009) 1.35
Tryptophan catabolism and T cell responses. Adv Exp Med Biol (2003) 1.34
Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol (2007) 1.32
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Physiologic control of IDO competence in splenic dendritic cells. J Immunol (2011) 1.29
Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol (2007) 1.27
Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol (2002) 1.23
Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest (2003) 1.23
Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci U S A (2008) 1.22
Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression. J Infect Dis (2011) 1.18
Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol (2012) 1.18
Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis. Am J Pathol (2004) 1.17
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood (2011) 1.16
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Current status of pediatric umbilical cord blood transplantation in Korea: a multicenter retrospective analysis of 236 cases. Am J Hematol (2011) 1.15
B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2010) 1.15
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J Immunol (2013) 1.13
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy (2009) 1.10
αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activation. J Cell Physiol (2011) 1.09
Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. J Immunol (2012) 1.06